These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17431753)

  • 1. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.
    Laplanche R; Meno-Tetang GM; Kawai R
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):373-400. PubMed ID: 17431753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.
    Moes DJ; Press RR; den Hartigh J; van der Straaten T; de Fijter JW; Guchelaar HJ
    Clin Pharmacokinet; 2012 Jul; 51(7):467-80. PubMed ID: 22624503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1219-29. PubMed ID: 23455451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125.
    Kawai R; Lemaire M; Steimer JL; Bruelisauer A; Niederberger W; Rowland M
    J Pharmacokinet Biopharm; 1994 Oct; 22(5):327-65. PubMed ID: 7791036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of everolimus.
    Kirchner GI; Meier-Wiedenbach I; Manns MP
    Clin Pharmacokinet; 2004; 43(2):83-95. PubMed ID: 14748618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
    Meno-Tetang GM; Li H; Mis S; Pyszczynski N; Heining P; Lowe P; Jusko WJ
    Drug Metab Dispos; 2006 Sep; 34(9):1480-7. PubMed ID: 16751263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
    O'Reilly T; McSheehy PM; Kawai R; Kretz O; McMahon L; Brueggen J; Bruelisauer A; Gschwind HP; Allegrini PR; Lane HA
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):625-39. PubMed ID: 19784839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.
    Kovarik JM; Hsu CH; McMahon L; Berthier S; Rordorf C
    Clin Pharmacol Ther; 2001 Sep; 70(3):247-54. PubMed ID: 11557912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats.
    Yokomasu A; Yano I; Sato E; Masuda S; Katsura T; Inui K
    Biopharm Drug Dispos; 2009 Dec; 30(9):517-23. PubMed ID: 19790241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats.
    Li X; DuBois DC; Almon RR; Jusko WJ
    J Pharmacol Exp Ther; 2020 Nov; 375(2):385-396. PubMed ID: 32883831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats.
    Yokomasu A; Yano I; Sato E; Masuda S; Katsura T; Inui K
    Drug Metab Pharmacokinet; 2008; 23(6):469-75. PubMed ID: 19122342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
    Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
    J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of sirolimus in rat tissue.
    Napoli KL; Wang ME; Stepkowski SM; Kahan BD
    Clin Biochem; 1997 Mar; 30(2):135-42. PubMed ID: 9127695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Δ
    Methaneethorn J; Poomsaidorn C; Naosang K; Kaewworasut P; Lohitnavy M
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):495-511. PubMed ID: 32266676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic Modeling: The Reversible Metabolism and Tissue-Specific Partitioning of Methylprednisolone and Methylprednisone in Rats.
    Yu R; Jusko WJ
    Drug Metab Dispos; 2024 Jun; 52(7):662-672. PubMed ID: 38653502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
    Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of therapeutic monitoring of everolimus in solid organ transplantation.
    Mabasa VH; Ensom MH
    Ther Drug Monit; 2005 Oct; 27(5):666-76. PubMed ID: 16175142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
    Budde K; Neumayer HH; Lehne G; Winkler M; Hauser IA; Lison A; Fritsche L; Soulillou JP; Fauchald P; Dantal J;
    Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Junghanss C; Rathsack S; Wacke R; Weirich V; Vogel H; Drewelow B; Mueller S; Altmann S; Freund M; Lange S
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1061-8. PubMed ID: 22182476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
    Tanaka C; O'Reilly T; Kovarik JM; Shand N; Hazell K; Judson I; Raymond E; Zumstein-Mecker S; Stephan C; Boulay A; Hattenberger M; Thomas G; Lane HA
    J Clin Oncol; 2008 Apr; 26(10):1596-602. PubMed ID: 18332467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.